Pharmacokinetics and Pharmacodynamics of Nasally Applied Esketamine

University Hospital, Basel, Switzerland1 site in 1 countryStarted: February 2009Last updated: December 2, 2010

Conditions

Interventions

Drugs

Trial Snapshot

Phase: Phase 1
Status: Completed
Sponsor
Locations: 1

Study Overview Eligibility Criteria Arms & Interventions Investigators Sites Records & Identifiers Similar Trials

Study Overview

Brief Summary

The purpose of this study is the determination of blood concentration and the effectiveness of esketamine after nasal application.

Study Design

Study Type: Interventional

Eligibility Criteria

Ages: 18 Years to 45 Years (Adult)
Sex: Male
Accepts Healthy Volunteers: Yes

Inclusion Criteria

•age ≥18 years ≤ 45 years
•non-smoking
•BMI 18-27

Exclusion Criteria

•abuse of drugs
•known or supposed hypersensitivity and/or contraindication against ketamine or additives
•participation of another clinical study within the last 30 days
•chronic obstructed nose breathing or nasal polyps
•dug allergy
•blood donation within the last two months

Arms & Interventions

Esketamine

Experimental

Intervention: esketamine hydrochloride (Drug)

Investigators

Sponsor

University Hospital, Basel, Switzerland

Sponsor Class

Other

Study Sites (1)

Loading locations...

Similar Trials

Terminated

Phase 1

Pharmacokinetic Study of Intranasal Dexmedetomidine in Pediatric Patients With Congenital Heart DiseaseDexmedetomidineCongenital Heart Disease

NCT03417999Children's Hospital of Philadelphia28

Completed

Phase 1

Investigating The Pharmacokinetics Of An Inhaled Dose Of A New Corticosteroid In Patients With Impaired Liver FunctionAsthma

NCT00419237GlaxoSmithKline20

Recruiting

Not Applicable

Bioequivalence Study of Somatropin in Healthy Human Volunteers..

IRCT20130626013776N20AryaTinaGene Biopharmaceutical Co30

Completed

Not Applicable

Bioequivalence Study of Pegfilgrastim in Healthy Human Volunteers

IRCT20130626013776N8AryaTinaGene Biopharmaceutical Co24

Completed

Phase 1

Investigation of Ascending Concentrations of Glycopyrronium Bromide (GPB) in a Topical Formulation in Subjects With Axillary HyperhidrosisPrimary Axillary Hyperhidrosis

NCT03037788Dr. August Wolff GmbH & Co. KG Arzneimittel30